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Abstract
Background: Cryptococcus gattii-induced cryptococcosis is an emerging infectious disease of humans and animals
with worldwide distribution and public health importance due to its significant morbidity and mortality rate. The present
study aimed to report a case of pulmonary infection by C. gattii molecular type VGII in State of São Paulo, Brazil.
Case presentation: A 5-year-old goat showing intermittent dry cough, ruminal tympany, anorexia, fever, tachycardia
and tachypnea was presented for necropsy at the Veterinary Hospital of the School of Veterinary Medicine and Animal
Sciences, São Paulo University, São Paulo, Brazil. Postmortem examination revealed numerous 2.0–6.0 cm diameter
yellow gelatinous pulmonary masses. Tissues were evaluated by a combination of pathological, mycological, and
molecular diagnostic techniques. Microscopically, pneumonia granulomatous, multifocal to coalescing, moderate,
with many intralesional carminophilic yeasts was observed. The immunohistochemistry and mycological culture
confirmed Cryptococcus spp. Internal transcribed spacers and orotidine monophosphate pyrophosphorylase nucleotide
differentiation demonstrated that the isolate corresponds to the C. gattii VGII molecular subtype.
Conclusions: To our knowledge, this is the first report of a pulmonary infection in a goat linked to C. gattii molecular
type VGII in Southeastern Brazil. Our findings emphasize the need for an active surveillance program for human and
animal new infections to improve the current public health policies due to expansion of the epidemiological niche of
this important microorganism.
Keywords: Cryptococcosis, Pneumonia, Goat, Yeast, Public health
Background
Cryptococcosis is a life-threatening systemic mycosis
affecting humans and a large variety of animals. The two
main pathogenic species are Cryptococcus neoformans
and Cryptococcus gattii [1]. C. neoformans, which has a
worldwide distribution, is an important cause of morbidity
and mortality in immunocompromised hosts (especially
AIDS-patients) and commonly found in bird feces, nests,
and tree bark. It is divided into the molecular types VN I
and VN II (var. Grubii, serotype A), VN III (serotype AD),
and VN IV (var. Neoformans, serotype D). Otherwise, C.
gattii, which is found in leaves, tree bark, and fruits in
tropical and subtropical areas as well as in eucalyptus
flowers and usually infects immunocompetent hosts, is
classified into serotypes B and C and into four molecular
types: VGI, VGII, VGIII, and VGIV [2, 3].
There are reports of cryptococcosis in different do-
mestic and wild animals. Dogs and cats become infected
by inhalation of spores through the nasal cavity, and the
infection spreads throughout the respiratory system and
often reaches the nervous system. In horses, sheep, and
goats, the lesions are restricted to the respiratory system;
while in cattle, lesions are usually located in the mam-
mary glands [4]. Wild animals such as koalas, snakes,
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ferrets, and porpoises can also be affected and show
different clinical manifestations, which are restricted to
lungs and central nervous system. In ferrets, Cryptococcus
spp. can affect the gastrointestinal and respiratory systems
such nasal cavity and eyes [5]. In contrast, there are few
reports of cryptococcosis in birds because these animals
are resistant to this fungal disease due to their high body
temperature (41–43 °C) [6]. In humans, after inhalation,
the disease progresses into the lungs, followed by in-
volvement of the innate immune system, occurs tissue
and macrophage invasion, and consequently, systemic
dissemination [7].
In caprines, reports of pulmonary cryptococcosis are
rare, and the main alterations observed include pleuro-
pneumonia, nasal congestion, mucopurulent exudate,
dyspnea, anorexia, and cachexia [8]. In Australia, skin
granulomas on the head region and nasal cavity involve-
ment were described in two goats [9, 10]. C. neoformans
is rarely diagnosed as a pneumonia-causing agent [10],
but according to Baró et al. [9], outbreaks in cattle and
caprines have been reported. C. neoformans infection is
occasionally reported in association with other diseases,
such as caprine arthritis, encephalitis, pleuropneumonia,
and neoplasms [11]. Thirteen autochthonous strains of
C. gattii serotype B was recently reported to cause severe
and disseminated pulmonary cryptococcosis in goats, as
well as outbreaks of pneumonia, with cachexia and in-
volvement of central nervous system in goats herds in
Spain, however, molecular genotype was not identified
[9]. In goats, C. gattii has been mainly associated with
respiratory diseases, while C. neoformans mainly affects
the central nervous system [12].
Cryptococcosis can be diagnosed by identification of
oval and encapsulated budding organisms during cytologic
examination of smears, histopathology, fungal isolation,
culture and molecular tests [10] or in a pre-mortem diag-
nosis by cytology or antigen search in serum by latex
agglutination [13]. Thus, the present study aimed to re-
port a case of C. gattii molecular type VGII infection in a
goat (Capra aegagrus hircus) as well as demonstrate and
discuss the different diagnostic methods available for small
ruminants.
Case presentation
A 5-year-old mixed-breed goat (Capra aegagrus hircus)
was necropsied at Veterinary Hospital of the School of
Veterinary Medicine and Animal Sciences, University of
São Paulo (HOVET/FMVZ-USP), São Paulo, Brazil. The
animal belonged to a pre-school located in the munici-
pality of Cotia, state of São Paulo, and was kept in a pas-
ture during the day, along with a horse and three ewes.
The goat was fed with alfalfa hay, feed and grazed in the
pasture. The goat had a history of ruminal tympany, ster-
num and limb edema, tachycardia, tachypnea, anorexia,
fever, and occasional diarrhea. Its owner reported that the
animal had an intermittent dry cough and was treated
with an orogastric tube in clinical crisis. However, the
animal had several relapses over a few days and was
taken to the HOVET/FMVZ-USP, when died during
transportation.
A complete necropsy was performed, and the macro-
scopic findings indicated an adequate body condition.
No ectoparasites, trauma signs, or marked abdominal
distention were present. The gross lesion was restricted
to the chest cavity, where 2.0 to 6.0 cm multiple nodular
masses were observed in the lungs (Fig. 1a) in cranial
and caudal portions of right cranial and in the middle
lobes of lung. The nodules were soft and drained a large
amount of yellow-whitish gelatinous content at cut (Fig. 1b).
Other organs showed no macroscopic alterations.
Tissue samples were collected and fixed in 10%
buffered formalin and cut in 5 μm sections and stained
with hematoxylin-eosin (HE) and Mayer’s Mucicarmin
for microscopical analyses. Microscopically, discrete
alveolar edema and multifocal, well-circumscribed cavity
areas were observed in the lungs. Within these foci there
were mild to moderate lymphoplasmacytic and histiocytic
inflammatory infiltrate, and rare neutrophils, associated
with numerous round extracellular yeasts structures with
variable capsular thickness, narrow-based budding, that
Fig. 1 Gross lesions of lungs. a The lung was distended and pink with reddish areas and there were multiple nodular areas in right cranial and
middle lobes. Bar = 4 cm. b Nodular areas containing yellow-whitish gelatinous content. Bar = 2 cm
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measured approximately 5.0–20 μm in diameter (Fig. 2a),
which stained weakly with HE and strongly stained the
capsule by Mayer’s Mucicarmin (Fig. 2b). These areas
were characterized of cryptococcomas.
Samples of lung were collected during the necropsy and
cultured in Sabouraud-dextrose broth and Sabouraud-
dextrose agar with chloramphenicol (100 mg/l), incubated
at 25 °C for three days or seven days, respectively, and
evaluated daily. Samples grown in Sabouraud-dextrose
broth were plated on Sabouraud-dextrose agar with chlor-
amphenicol (100 mg/l), which was incubated as previously
described. Beige, mucoid, bright, and viscous colonies with
a milky aspect were subjected to morphological evaluation
using China ink for capsule visualization. Biochemical
tests such as urease, sugar assimilation (glucose, galactose,
lactose, melibiose, and sucrose) and potassium nitrate
(KNO3) tests, as well as evaluation of growth at 37 °C
and in media containing cycloheximide, were per-
formed. These tests were performed as described by
Lacaz et al. [14] and Larone [15], and their results con-
firmed identification of the fungal agent as a member
of the Cryptococcus spp. complex.
Histological sections of lungs were subjected to immu-
nohistochemistry using antibody-specific for Cryptococcus
spp. Histological sections (3 μm) were subjected to an
antigen retrieval protocol in 10 mM citric acid solution
(pH 6.0) in a pressure cooker for three minutes at 120 °C.
Subsequently, endogenous peroxidase was blocked with
H2O2 for 30 min, followed by non-specific binding
blocking (Protein Block - PictureMax Kit™ Life
Technologies, Carlsbad, California, USA) for 15 min.
The anti-Cryptococcus polyclonal primary in house
antibody was diluted in phosphate buffered saline (PBS)
solution with 1% bovine serum (pH 7.4; 1:50,000), and
the slides were incubated with primary antibody over-
night at 4 °C. This primary antibody was purified from
immunoglobulin fraction of rabbit antiserum, injected
with an isolate of Cryptococcus gatti (LMM21) serotype B
(MAT-alpha), VGII/AFLP6 as described by Kidd et al. [16]
and Lourenço [17]. The antibody was tested in immuno-
histochemistry for reactivity with a variety of organisms.
No cross-reactivity was observed with Histoplasma
capsulatum, Candida, Pneumocystis carinii, Cryptosporidia
and Mycobacterium tuberculosis.
Signal amplification was performed with a PictureMax
Kit™ (Life Technologies, Carlsbad, California, USA) for
30 min at 37 °C. Thereafter, the staining was revealed by
100 mg of 3,3′-diaminobenzidine (DAB D-5637; Sigma,
St. Louis, Missouri, USA) diluted in PBS (pH 7.4) at 37 °C
for three minutes, and counter-staining was performed
with Harris’ hematoxylin. Reaction was observed with an
optical microscope, which confirmed the presence of
structures that were positively stained and compatible
with Cryptococcus spp. (Fig. 2c).
Genotype of fungus was achieved through PCR and
sequencing. Initially, DNA was extracted from frozen
lung tissue fragments, stored at -80 °C, according to the
manufacturer’s instructions (Illustra tissue and cells
genomic Prep Mini Spin Kit - GE Healthcare, USA). DNA
quality and concentration were evaluated by analyzing
the integrity and purity of the samples with a NanoDrop
(NanoDrop Technologies, Wilmington, Delaware, USA).
PCR was performed based on the protocols of Mirhendi
et al. [18] and Meyer et al. [19] using the primers ITS1
(5′-TCCGTAGGTGAACCTGCGG-3′) and ITS4 (5′-
TCCTCCGCTTATTGATATGC-3′); URA5 (5′-ATGTCC
TCCCAAGCCCTCGACTCCG-3′) and SJ01 (5′-TTAAG
ACCTCTGAACACCGTACTC-3′). Approximately 100 ng
of DNA was used for each PCR reaction and FastStart
PCR Master (Roche, Rotkreuz, Switzerland) in a 25 μl reac-
tion volume. Solution was initially incubated at 94 °C for
three minutes for denaturation, followed by 40 cycles of
94 °C for one minute, 58 °C for the first primer pair and
61 °C for the second primer pair for one minute, and 72 °C
for one minute, and a final extension of 72 °C for 10 min.
Amplicons were visualized on a 2% agarose gel and
photographed using an Image Master VDS (Pharmacia
Biotech, USA). RNase and DNase free ultra-pure water
Fig. 2 Lung photomicrography. a Well-circumscribed cavitations areas of granulomatous pneumonia associated pleomorphic, yeast structures
with mucinous capsule of variable thickness which show clear and refractile halo (HE stain, bar = 25 μm). b Yeast in details with oval to round,
and 5–20 μm in diameter organism’s structure which capsule (carminophilic) stain in red inside of cavitations areas (cryptococcomas). (Mayer’s
Mucicarmin stain, bar = 50 μm). c Cryptococcal antigen was detected by immunohistochemistry using anti-Cryptococcus polyclonal antibody,
1:50,000 diluted. Positive yeast structures stained in strong brown for Cryptococcus spp. PictureMax Kit™, DAB stain, bar = 25 μm
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was used as a negative control (UltraPure™DEPC- Treated
Water, Invitrogen, USA). PCR product was sequenced by
the Center for Human Genome Studies, Institute of
Biosciences-USP after purification using a commercial kit,
according to the manufacturer’s instructions (QIAquick
PCR Purification Kit, QIAgen, Hilden, Germany). For
sequencing, 4 μL of BigDye 3 (BigDye Terminator v3.1
Cycle Sequencing Kit, Applied Biosystems, USA), 4 μL of
5X buffer, 0.5 μL of each primer (10 μM ITS1, ITS4,
URA5, and SJ01) in separate reactions, 40 ng of target
DNA, and RNase- and DNase-free ultra-pure water were
used for a final reaction volume of 20 μL in a capillary
automated sequencer (ABIPrism 3730 DNA Analyser,
Applied Biosystems, USA). The quality of the chromato-
grams generated for each primer (forward and reverse) of
each sample was evaluated using the online application
Phred (http://asparagin.cenargen.embrapa.br/phph/) and
then manually edited using the Chromas Lite v. 2.1.1. soft-
ware (http://technelysium.com.au/?page_id=13). The final
sequence of each sample was obtained using the appli-
cation Cap-contig of the BioEdit v.5.0.9 software
(www.mbio.ncsu.edu/bioedit/bioedit.html) and subjected
to a homology search for other sequences deposited in
GenBank using the Blast 2.2.29 software (http://www.
ncbi.nlm.nih.gov/blast/).
The sequencing results showed 100% homology to a
region of the internal transcript sequence 1 (ITS1) of the
ribosomal DNA amplified with C. gattii strain [GenBank
acc # JQ812708 (ATCC MYA-4877)] and 99% homology
to IDR1100011626 (GenBank acc # JN675352). More-
over, orotidine monophosphate pyrophosphorylase gene
(URA5) signature sequence from this isolate exactly
matched that of C. gattii corresponds with PCR-
fingerprint molecular type VGII.
Discussion
C. gattii is recognized as the main agent of endemic pri-
mary cryptococcosis in the North and Northeast (NE)
Region of Brazil, where it is responsible for 89% of hu-
man cryptococcosis, and has the potential to cause life-
threatening disease in immunocompetent hosts and [20].
The first VGII strain (LMM 293) identified in Brazil was
isolated in Rio de Janeiro in 1988 from a patient coming
from the NE [21]. In 1999, a total of 19 cases of crypto-
coccosis, nine of them caused by C. gattii infections,
were described in children in Pará [22]. In the same re-
gion, an other study, showed that C. gattii is an endemic
primary mycosis affecting HIV-negative hosts, with most
cases caused by molecular type VGII, including an unex-
pectedly high number of children, [22, 23].
Most of the clinical isolates of VGII in the states of
Rio de Janeiro and São Paulo have been collected from
patients born in Northeastern Brazil [24]. In South and
Southeast Brazil, 43% of C. gattii infections are caused
by VGII [21]. However, a diagnosis of meningoencephalitis
caused by a VGII strain in a 5-year-old child who has lived
all his life in the state of Rio de Janeiro suggests that the
VGII strain may be spreading from the Northeast to
Southeast region of Brazil. In addition, C. gattii has been
the agent of one outbreak in captive psittacine birds in
São Paulo, Brazil [25].
Also, C. gattii molecular type VGII was described as a
primary emerging pathogen on Vancouver Island,
Canada, and, subsequently, spread to people and animals
in British Columbia, Washington and Oregon. Retro-
spective studies suggested that C. gattii may have circu-
lated in Southern California for much longer. The
mechanism of the switch from tropical to temperate cli-
mates is unknown. However, most eucalyptus associated
outbreaks in Australia are of molecular type VGI,
whereas 90% of isolates from the Pacific Northwest are
type VGIIa, and southern California isolates are type
VGIII, the genotype commonly identified in Mexico.
This suggests that different genotypes have different
biogeoclimatic distributions [26–28].
C. gattii can acts as a primary pathogen and causes
endemic cryptococcosis, including meningoencephalitis,
in HIV-negative patients. However, fully competent im-
mune response in these hosts has been questioned, since
infection with C. gattii is increasingly linked to the presence
of various types of autoantibodies, which interfere with the
host defenses, like anti-granulocyte-macrophage colony-
stimulating factor [29].
Cryptococcus is the most common systemic mycosis in
cats and often results in a severe disseminated disease in
dogs [30]. According to Torres-Rodríguez et al. [31], the
large number of cats and dogs diagnosed with crypto-
coccosis might be related to evident clinical signs, which
facilitate the diagnosis. In other species of domestic
animals such as cattle, horses, sheep, and goats, the final
diagnosis depends on anatomopathological findings, which
hinders the diagnosis. The increased incidence of disease
associated with C. gattii can be attributed to three factors:
environmental expansion, a lack of diagnostic tests, and
the increased frequency of identification by molecular de-
tection procedures [32]. Epidemiological studies of crypto-
coccosis are difficult because fungus species identification
is rarely performed [33]. Byrnes et al. [34], emphasize that
determination of the molecular type is very important in
the clinical and epidemiological clarification of the disease,
which highlights the importance of the present study.
Treatment options for cryptococcal infections are de-
pendent on the severity and localization of the infection.
In humans, treatment guidelines from the Infectious
Diseases Society of America (IDSA) recommend treat-
ment of severe cases of cryptococcosis in immunocompe-
tent and immunocompromised patients using induction
therapy for 2 weeks with a combination of
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amphotericin B and 5-flucytosine, followed by 2 weeks
of consolidation therapy using fluconazole [35]. Com-
pared to C. neoformans, infections with C. gattii might
need a more aggressive antifungal therapy due to the
higher probability of severe neurological complications
and possible delayed response to used antifungal com-
pounds in humans [36]. It has been observed that in
vitro antifungal susceptibilities significantly differ be-
tween genotype VGI and VGII C. gattii strains, which
might affect the outcome of antifungal therapy, and
which is an indication that in vivo differences may
exist [35]. Dose and length of treatment with oral
fluconazole for Cryptococcus spp. was established on
available literature in horses, cats and dogs [37–39].
However, in ruminants, the bioavailability of oral medica-
tions usually varies from that in monogastric animals, so
intravenous administration has been preferred. One goat
with cryptococcal infection in cesarean incision site was
treated daily with oral fluconazole for 6 months; however
it demonstrated a cryptococcoma peritoneal recurrence
after 2 years from the first diagnosis [12].
Despite the few epidemiological studies available in
humans and animals, molecular subtype VGII does not
seen to be a rare genotype of C. gattii in South America.
In fact, it behaves as a primary fungal pathogen and
causes endemic cryptococcosis in immunocompetent
hosts in the northern region of Brazil, where it is par-
ticularly well-adapted to environmental biotypes associ-
ated with wood decay. However, this molecular type may
be adapting to new areas in the southeast due to human
activities and global climate change, or it may be present
at a low density in the southeast, causing occasional hu-
man infections [21].
Conclusion
Histopathology, immunohistochemistry, microbiology, and
molecular test are important to determine infectious agents
and their differential diagnosis in cases of systemic respira-
tory diseases in small ruminants. To our knowledge, this is
the first report of a pulmonary infection linked to C. gattii
molecular type VGII in a goat in state of São Paulo, Brazil.
Our findings emphasize the need for an active surveillance
program for human and animal infections due to expansion
of the epidemiological niche of this important zoonotic
microorganism.
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